- Primary research
- Open Access
An isolated case of lissencephaly caused by the insertion of a mitochondrial genome-derived DNA sequence into the 5' untranslated region of the PAFAH1B1(LIS1) gene
© Henry Stewart Publications 2010
- Received: 27 May 2010
- Accepted: 27 May 2010
- Published: 1 August 2010
A 130 base pair (bp) insertion (g.-8delCins130) into the 5' untranslated region of the PAFAH1B1 (LIS1) gene, seven nucleotides upstream of the translational initiation site, was detected in an isolated case of lissencephaly. The inserted DNA sequence exhibited perfect homology to two non-contiguous regions of the mitochondrial genome (8479 to 8545 and 8775 to 8835, containing portions of two genes, ATP8 and ATP6), as well as near-perfect homology (1 bp mismatch) to a nuclear mitochondrial pseudogene (NUMT) sequence located on chromosome 1p36. This lesion was not evident on polymerase chain reaction (PCR) sequence analysis of either parent, indicating that the mutation had occurred de novo in the patient. Experiments designed to distinguish between a mitochondrial and a nuclear genomic origin for the inserted DNA sequence were, however, inconclusive. Mitochondrial genome sequences from both the patient and his parents were sequenced and found to be identical to the sequence inserted into the PAFAH1B1 gene. Analysis of parental PCR products from the chromosome 1-specific NUMT were also consistent with the interpretation that the inserted sequence had originated directly from the mitochondrial genome. The chromosome 1-specific NUMT in the patient proved to be refractory to PCR analysis, however, suggesting that this region of chromosome 1 could have been deleted or rearranged. Although it remains by far the most likely scenario, in the absence of DNA sequence information from the patient's own chromosome 1-specific NUMT, we cannot unequivocally confirm that the 130 bp insertion originated from mitochondrial genome rather than from the NUMT.
- PAFAH1B1 gene
- mitochondrial genome
Classical (type 1) lissencephaly is a neuronal migration disorder characterised by agyria (absent cerebral convolutions) and pachygyria (reduced, broad cerebral convolutions), a thickened cortex (grey matter), mental retardation and epileptic seizures. It can occur either as part of the contiguous deletion disorder, Miller-Dieker syndrome, or as an isolated condition termed isolated lissencephaly sequence (ILS) . Most cases of ILS are caused by defects in either the PAFAH1B1 (LIS1) or the DCX genes. Patients with a PAFAH1B1 gene alteration have a more severe cerebral phenotype posteriorly, whereas those with a DCX gene defect have a more severe cerebral phenotype anteriorly. The heterozygous deletion of a further gene, YWHAE (located 1 megabase [Mb] from PAFAH1B1 on 17p13.3 and encoding the 14-3-3ε protein), together with PAFAH1B1 in patients with Miller-Dieker syndrome, is known to increase the severity, usually with generalised agyria .
The PAFAH1B1 gene (MIM# 601545) was the first gene to be implicated in the pathogenesis of lis-sencephaly and encodes the non-catalytic α-subunit of the intracellular 1b isoform of platelet-activating factor acetylhydrolase . It spans ~92 kilobases (kb) of genomic DNA and contains 11 exons, the first two of which contribute to the 5' untranslated region (5' UTR). Although the deletion of the entire PAFAH1B1 gene is the most common mutation encountered in lissencephaly patients, a considerable number of intragenic lesions have now been reported [4–8]. In general, however, it appears that neither the type nor the position of known intragenic mutations in the PAFAH1B1 gene are indicative of the likely clinical severity of the condition . Here, we report a highly unusual lissencephaly-causing mutation in the PAFAH1B1 gene, which involves the insertion of mitochondrial genome-derived DNA sequence into the 5' UTR of the gene.
PCR and sequencing
Exons 2 to 11 of the human PAFAH1B1 gene were polymerase chain reaction (PCR) amplified (primer details in Table S1) and the resulting products were gel-purified (Gel Extraction Kit, Qiagen, Crawley, UK). Purified PCR products were then sequenced using BigDye v3.1 (Applied Biosystems, Warrington, UK) and analysed on an ABI 3100 genetic analyser (Applied Biosystems, Warrington, UK). PCR primers specific for either the chromosome 1 nuclear mitochondrial pseudogene (NUMT) sequence (accession number NT_004350.19) or the mitochondrial genome sequence (accession number NC_001807.4) were as follows: chromosome 1-specific primers -- CHR15 (5' TGTGGAGCAAACCAGTTTTATG 3', 47366 to 47387) and CHR13 (5' CTGAGTAGCTACAG TACATATC 3', 49106 to 49127); mitochondrial genome-specific primers -- MITO5 (5' GTGGAGC AAACCACAGTTTC 3', 8185 to 8204) and MITO3 (5' GGATGAAGCAGATAGTGAGG 3', 9849 to 9869). PCR was performed using the Expand™ high fidelity system (Roche, East Sussex, UK) using a hot start of 98°C for three minutes followed by 95°C for two minutes, 35 cycles at 95°C for 45 seconds, 60°C for 30 seconds and 72°C for one minute. For the last 25 cycles, the elongation step at 72°C was increased by five seconds per cycle, followed by a further incubation at 72°C for ten minutes. PCR products were then sequenced with primers common to both the chromosome 1 sequence and the mitochondrial genome as follows: CHRMITF (5' AACCAACACCTCTTTACAGTG 3'; Chr1 47524 to 47544 and mitochondrial genome 8344 to 8364) and CHRMITR (5' TGAGTAGGCTGATGGTTTCG 3'; Chr1 48139 to 48158 and mitochondrial genome 8959 to 8978).
Chromosome 1-specific regions around the identified NUMT were PCR amplified with different combinations of the primers listed in Table S2. All PCRs were performed using the Expand™ high-fidelity system under the following conditions: 98°C for three minutes, followed by 95°C for two minutes, 35 cycles of 95°C for 45 seconds, 60°C for 30 seconds and 68°C for four minutes. For the last 25 cycles, the elongation step at 68°C was increased by five seconds per cycle. This was followed by a further incubation at 68°C for ten minutes. To ensure that the PCR products were derived from chromosome 1, partial sequencing of each product obtained was performed with the appropriate primers using BigDye v3.1 and analysed on an ABI 3100 genetic analyser.
To elucidate the mechanism of the PAFAH1B1 insertion, a BLAST search http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome of the inserted fragment was performed against the Human Genomic Sequences and Transcripts Database http://www.ncbi.nlm.nih.gov/Tools. The MegaBLAST option, designed to identify highly homologous sequences, was used. Two sequences were found to yield a significant alignment - namely, a sequence from the mito-chondrial genome (100 per cent homology; ref NC_001807.4) and a NUMT sequence located on chromosome 1 (98 per cent homology; ref NT_004350.19).
Sequences flanking the inserted fragments in the mitochondrial genome, as well as the sequences flanking the insertion site in the PAFAH1B1 gene, were screened for the presence of direct repeats, inverted repeats and symmetric elements (both within each sequence and between them) by means of complexity analysis .
RNA secondary structure was analysed using RNAfold from the Vienna RNA package http://rna.tbi.univie.ac.at using default parameters. Identification of putative splice sites was performed using the Berkeley Drosophila Genome Project package http://www.fruitfly.org/seq_tools/splice.html to analyse the wild-type and mutant (insertion-containing) exon 2 sequences of the PAFAH1B1 gene flanked by 50 base pairs (bp) of intronic DNA sequence. The minimum score for both acceptor and donor splice sites was set at 0.8.
The patient was born, after an uneventful pregnancy and delivery, weighing 3.4 kg. He was the younger of two siblings born to non-consanguineous Caucasian parents. His very early motor milestones were acquired age appropriately, and his overall development was normal until eight months of age, at which time he had a febrile fit and lost some of his acquired skills. When referred at the age of 15 months, his development was at an approximate age level of six to eight months. Seizures developed at four years of age, but these were well controlled with sodium valpro-ate and lamotrigine. They were a combination of tonic/clonic, 'star' seizures (tonic extension) and brief atonic attacks. By this time, global developmental delay was evident. He was first seen for a genetics review at the age of ten years. His gait was unsteady, with a tendency to fall frequently or bump into objects. He was able to walk short distances but longer distances required the use of a wheelchair. Although he was able to walk upstairs holding onto a rail, he descended stairs on his bottom. He spoke a few solitary words and could obey simple commands. He was not dysmorphic, but had a degree of brachycephaly. His head circumference was on the 75th centile, weight on the 98th centile and height on the 25th centile. He had relatively small genitalia, but no neurocutaneous stigmata.
The patient had a normal 46XY karyotype, with no evidence of a microdeletion at the Miller-Dieker locus on 17p13.3. His EEG at the age of six years was abnormal, with frequent showers of sharp waves or spikes throughout the recording. This was more obvious in the anterior brain regions, with some emphasis on the left side. A magnetic resonance imaging (MRI) brain scan at eight years of age revealed frontal, parietal, posterior temporal and occipital pachygyria, with maximal cortical thickening posteriorly. The degree of pachygyria was also milder anteriorly. Appearances were consistent with classical lissencephaly at the milder end of the spectrum, and a posterior to anterior severity consistent with the presence of a PAFAH1B1 (LIS1) gene mutation. In view of the highly unusual PAFAH1B1 gene insertion found in this patient, genomic DNA from this individual was also screened for DCX gene mutations, but none were found.
Microsatellite marker analysis was used to confirm that familial relationships were as stated at referral (data not shown).
Sequence analysis of the PAFAH1B1gene in the patient
Origin of the inserted DNA sequence with homology to the mitochondrial genome
Inspection of the sequence flanking the junction between the 67 bp and 61 bp fragments identified two short imperfect direct repeats, GAAGC and GGAGG, in the mitochondrial genome (8546 to 8550 and 8776 to 8780, respectively; accession number NC_001807.4) which could have mediated the loss of the 229 bp fragment through slipped mispairing. It should be noted that the equivalent sequences in the chromosome 1 NUMT are GAAGT and GGAGG (47728 to 47732 and 47956 to 47960, respectively; accession number NT_004350.19).
The inserted sequence contains portions of two mitochondrial genes, ATP8 (8367 to 8573; accession number NC_001807.4) and ATP6 (8528 to 9208; accession number NC_001807.4), but whether the inserted sequence was derived from the mitochondrial genome itself or from a reverse transcript of mRNA encoding the ATP6 and ATP8 mitochondrial genes cannot be ascertained from the DNA sequence involved.
Since the mitochondrial genome and chromosome 1-specific NUMT sequences differed from each other by only 1 bp over the 130 bp length of the insert, it was considered important to establish whether the patient's own mitochondrial genome and chromosome 1-specific NUMT sequences were identical to their respective published reference sequences. Oligonucleotide primers were therefore designed specifically to PCR amplify DNA fragments corresponding to the inserted sequence from either the mitochondrial genome or chromosome 1. PCR products from the mitochon-drial genome of both the patient and his parents were sequenced and found to be identical to (but not, of course, contiguous with) the sequence inserted into the PAFAH1B1 gene. Similarly, PCR/direct sequencing of the chromosome 1-specific NUMT from both the patient's parents confirmed sequence identity with the standard chromosome 1 reference sequence (ie 1 bp mismatch with respect to the PAFAH1B1 gene insertion). Attempts to PCR amplify the chromosome 1-specific NUMT sequence from the patient repeatedly failed to yield any PCR product, however. To confirm that the nuclear DNA from the patient was of good quality, PCR amplification of a 3.2 kb fragment containing the GH1 gene  was performed. Successful PCR amplification of this fragment from patient DNA (data not shown) indicated that the lack of PCR amplification of the chromosome 1-specific NUMT was not due to poor DNA quality. The reason why the patient's chromosome 1-specific NUMT was refractory to analysis remains unclear but is potentially interesting, given the possible involvement of this sequence in the PAFAH1B1 gene insertion. Although it remains the most likely scenario, in the absence of DNA sequence information from the patient's own chromosome 1-specific NUMT, we cannot unequivocally confirm that the 130 bp insertion originated from the mitochondrial genome sequence rather than from the NUMT.
In order to ascertain whether the patient possessed a deletion of chromosome 1p36 encompassing the chromosome 1-specific NUMT, an attempt was made to PCR amplify across the NUMT sequence. Combinations of different chromosome 1-specific primers (Table S2) were employed to amplify different DNA sequences between 43,267 and 53,538 (accession Number NT_004350.19) in both the patient and his parents. PCR products of the appropriate sizes were amplified from both parents and, on sequencing, were confirmed to match the chromosome 1-specific NUMT sequence. No PCR product from the chromosome 1-specific NUMT was obtained from the patient for any combination of primers used, however, suggesting that this region of chromosome 1 may have been homozygously deleted, rearranged or both.
Analysis of the inserted sequence and the site of insertion in the PAFAH1B1gene
Since the identified insertion lies within the 5' UTR of the PAFAH1B1 gene, it has the potential to have an impact on RNA secondary structure. Using RNAfold, the optimal secondary structure minimum free energy was determined to be -249.0 kcal/mol for the wild-type 5' UTR, whereas for the mutant 5' UTR (containing the insertion), this value was -299.6 kcal/mol. This suggests that the stability of the 5' UTR may not have been dramatically altered by the insertion; however, the predicted secondary structure of the mutant 5' UTR molecule was clearly very different from that of the wild-type 5' UTR (Figure S1).
Differences in pre-mRNA structure resulting from single bp substitutions have been reported to result in aberrant splicing . Prediction of splice sites in the wild-type PAFAH1B1 sequence using NNSPLICE software  attributed the experimentally validated exon 2 acceptor (position 50; Figure 3) and donor (position 401; Figure 3) splice sites with potential splice site scores of 0.97 and 1.00, respectively. When the analysis was repeated for the mutant PAFAH1B1 sequence, an additional acceptor splice site was predicted (position 325, score 0.91; Figure 3) in addition to the wild-type splice sites. Without in vitro splicing analysis, however, it remains unclear whether this additional acceptor splice site would be functionally significant.
Mechanism of mutagenesis
Sequence analysis of the coding region of the lissencephaly patient's PAFAH1B1 gene revealed a heterozygous 130 bp insertion within exon 2. Since this lesion could not be detected by sequence analysis of either parent, it would appear that the mutation occurred de novo in the patient. The inserted sequence was found to be perfectly homologous to two non-contiguous (separated by 229 bp) sequences in the mitochondrial genome reference sequence, of length 67 bp and 61 bp, respectively. We propose that the intervening 229 bp fragment may have been lost during the process of insertion into the PAFAH1B1 gene. This postulate is supported by the presence of two short imperfect direct repeats (GGAGG and GAAGC), flanking the junction between the 67 bp and 61 bp fragments, which could have mediated the loss of the 229 bp fragment through slipped mispairing.
The inserted sequence contains portions of two mitochondrial genes, ATP8 and ATP6, but the sequence itself is too short to be able to determine unequivocally whether it was derived from the mitochondrial genome or from a reverse transcript of mRNA derived from the two mitochondrial genes. On the basis that (i) there is no correlation between NUMT frequency and the abundance of their cognate transcripts  and (ii) there is no preference for the integration of NUMTs from transcribed regions as opposed to non-transcribed regions, [18, 19] we therefore surmise that the composite 130 bp insertion is likely to have been of mito-chondrial genome origin.
Near-perfect homology (one bp mismatch) was, however, also found between the 130 bp insertion in the PAFAH1B1 gene and a NUMT sequence at chromosome 1p36, raising the possibility that the insert could conceivably have been of nuclear origin. Experiments designed to distinguish between a mitochondrial and a nuclear genomic origin were, however, inconclusive. Analysis of parental PCR products from both the mitochondrial genome and the chromosome 1-specific NUMT was consistent with the interpretation that the insertion had originated directly from the mito-chondrial genome (although a heterozygous chromosome 1-specific NUMT deletion would not have been detected). This concurs with the finding that most newly arising NUMTs derive from the independent insertion of mitochondrial genome fragments, rather than from the duplicational transposition of pre-existing NUMTs . No PCR product from the chromosome 1-specific NUMT could be obtained from the patient, however, suggesting that this region of chromosome 1 may have been specifically deleted, rearranged or both. If confirmed, the concomitant occurrence of a chromosome 1 rearrangement could be suggestive of the involvement of this locus in the insertion into the PAFAH1B1 gene in our patient; however, it might also be sheer coincidence.
Although we can offer no formal confirmation that the 130 bp insertion either alters or abolishes the expression of the PAFAH1B1 gene, we believe that this is very likely to be the case on account of the site of insertion within the 5' UTR only seven nucleotides upstream of the translational initiation site. 5' UTRs contain a variety of cis-regulatory elements which influence translation and hence, when disrupted by mutation, can cause inherited disease [21, 22]. We have presented some indirect evidence to support the view that this large insertion may have affected the translation of the PAFAH1B1 mRNA by either destabilising the secondary structure of the 5' UTR or by altering the splicing phenotype. Gross insertions into 5' UTRs are extremely unusual as a cause of inherited disease; a comparable example of a 75 bp insertion (of non-mitochondrial origin) has, however, been reported in the 5' UTR of the RFXAP gene of a patient with major histocompatibility complex (MHC) class II deficiency, which served to silence the gene . This example certainly supports the contention that such an insertion within the 5' UTR can have a profound effect on the expression of the downstream gene. In view of the comparatively mild clinical phenotype exhibited by the lissence-phaly patient reported here, however, we speculate that some residual PAFAH1B1 gene expression may have served to ameliorate the severity of the condition in this particular case.
No sequence homology was found between the mitochondrial DNA insert and the site of insertion in the PAFAH1B1 gene. Taken together with the identification of two non-templated bases (TT) at the 5' end of the inserted sequence and the deletion of a cytosine 5' to the breakpoint in the PAFAH1B1 gene, this lesion would therefore appear to be compatible with a mutational model that combines features of non-homologous end-joining with 'NUMT-mediated double-strand break repair' [13, 24]. We speculate that some of the repetitive sequence elements that we identified in the vicinity of the PAFAH1B1 gene could have given rise to a double-strand break which was then subsequently repaired by integration of the mito-chondrial DNA fragment.
Oligonucleotide primers used for the PCR amplification and sequencing of exons 2-11 of the human PAFAH1B1 gene.
Sequence (5' to 3')
44547 - 44567
44760 - 44780
71646 - 71667
71890 - 71911
72334 - 72355
72516 - 72537
73327 - 73349
73641 - 73660
76489 - 76508
76771 - 76790
78939 - 78959
79229 - 79248
80374 - 80393
80684 - 80706
82824 - 82844
83028 - 83050
86481 - 86502
86726 - 86746
88035 - 88057
88210 - 88232
Oligonucleotide primers designed to PCR amplify the chromosome 1-specific NUMT.
Sequence (5' to 3')
43267 - 43287
44637 - 44656
45677 - 45695
46870 - 46889
50894 - 50912
51602 - 51622
52627 - 52647
53518 - 53538
The authors would like to thank Dr Elaine Hughes (consultant paediatric neurologist) and Dr Sian Bennett (consultant community paediatrician) for their contributions in the clinical investigation of this patient.
- Wynshaw-Boris A: Lissencephaly and LIS1: Insights into the molecular mechanisms of neuronal migration and development. Clin Genet. 2007, 72: 296-304. 10.1111/j.1399-0004.2007.00888.x.View ArticlePubMedGoogle Scholar
- Cardoso C, Leventer RJ, Ward HL, Toyo-Oka K, et al: Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. Am J Hum Genet. 2003, 72: 918-930. 10.1086/374320.PubMed CentralView ArticlePubMedGoogle Scholar
- Lo Nigro C, Chong CS, Smith AC, Dobyns WB, et al: Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome. Hum Mol Genet. 1997, 6: 157-164. 10.1093/hmg/6.2.157.View ArticlePubMedGoogle Scholar
- Cardoso C, Leventer RJ, Dowling JJ, Ward HL, et al: Clinical and molecular basis of classical lissencephaly: Mutations in the LIS1 gene (PAFAH1B1). Hum Mutat. 2002, 19: 4-15. 10.1002/humu.10028.View ArticlePubMedGoogle Scholar
- Saillour Y, Carion N, Quelin C, Leger PL, et al: LIS1-related isolated lissencephaly: Spectrum of mutations and relationships with malformation severity. Arch Neurol. 2009, 66: 1007-1015. 10.1001/archneurol.2009.149.View ArticlePubMedGoogle Scholar
- Mei D, Lewis R, Parrini E, Lazarou LP, et al: High frequency of genome deletions and a duplication in the L1S1 gene in lissencephaly: Implications for molecular diagnosis. J Med Genet. 2008, 45: 355-361. 10.1136/jmg.2007.056507.View ArticlePubMedGoogle Scholar
- Human Gene Mutation Database. [http://wwwhgmdorg]
- Stenson PD, Mort M, Ball EV, Howells K, et al: The Human Gene Mutation Database: 2008 update. Genome Med. 2009, 1: 13-10.1186/gm13.PubMed CentralView ArticlePubMedGoogle Scholar
- Uyanik G, Morris-Rosendahl DJ, Stiegler J, Klapecki J, et al: Location and type of mutation in the LIS1 gene do not predict phenotypic severity. Neurology. 2007, 69: 442-447. 10.1212/01.wnl.0000266629.98503.d0.View ArticlePubMedGoogle Scholar
- Gusev VD, Nemytikova LA, Chuzhanova NA: On the complexity measures of genetic sequences. Bioinformatics. 1999, 15: 994-999. 10.1093/bioinformatics/15.12.994.View ArticlePubMedGoogle Scholar
- Gruber AR, Lorenz R, Bernhart SH, Neuböck R, et al: The Vienna RNAWebsuite. Nucleic Acids Res. 2008, 36: W70-W74. 10.1093/nar/gkn188.PubMed CentralView ArticlePubMedGoogle Scholar
- Reese MG, Eeckman FH, Kulp D, Haussler D: Improved splice site detection in Genie. J Comp Biol. 1997, 4: 311-323. 10.1089/cmb.1997.4.311.View ArticleGoogle Scholar
- Hazkani-Covo E, Zeller RM, Martin W: Molecular pol-tergeists: Mitochondrial DNA copies (numts) in sequenced nuclear genomes. PLoS Genet. 2010, 6: e1000834-10.1371/journal.pgen.1000834.PubMed CentralView ArticlePubMedGoogle Scholar
- Millar DS, Lewis MD, Horan M, Newsway V, et al: Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulations of the clinical selection criteria for individuals with short stature. Hum Mutat. 2003, 21: 424-440. 10.1002/humu.10168.View ArticlePubMedGoogle Scholar
- Kozak M: Pushing the limits of the scanning mechanism for initiation of translation. Gene. 2002, 299: 1-34. 10.1016/S0378-1119(02)01056-9.View ArticlePubMedGoogle Scholar
- Buratti E, Baralle FE: Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol. 2004, 24: 10505-10514. 10.1128/MCB.24.24.10505-10514.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Woischnik M, Moraes CT: Pattern of organization of human mitochondrial pseudogenes in the nuclear genome. Genome Res. 2002, 12: 885-893.PubMed CentralView ArticlePubMedGoogle Scholar
- Henze K, Martin W: How do mitochondrial genes get into the nucleus?. Trends Genet. 2001, 17: 383-387. 10.1016/S0168-9525(01)02312-5.View ArticlePubMedGoogle Scholar
- Mourier T, Hansen AJ, Willerslev E, Arctander P: The Human Genome Project reveals a continuous transfer of large mito-chondrial fragments to the nucleus. Mol Biol Evol. 2001, 18: 1833-1837. 10.1093/oxfordjournals.molbev.a003971.View ArticlePubMedGoogle Scholar
- Bensasson D, Feldman MW, Petrov DA: Rates of DNA duplication and mitochondrial DNA insertion in the human genome. J Mol Evol. 2003, 57: 343-354. 10.1007/s00239-003-2485-7.View ArticlePubMedGoogle Scholar
- Pickering BM, Willis AE: The implications of structured 5' untranslated regions on translation and disease. Semin Cell Devel Biol. 2005, 16: 39-47. 10.1016/j.semcdb.2004.11.006.View ArticleGoogle Scholar
- Chatterjee S, Pal JK: Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell. 2009, 101: 251-262. 10.1042/BC20080104.View ArticlePubMedGoogle Scholar
- van Eggermond MC, Tezcan I, Heemskerk MH, van den Elsen PJ: Transcriptional silencing of RFXAP in MHC class II-deficiency. Mol Immunol. 2008, 45: 2920-2928. 10.1016/j.molimm.2008.01.026.View ArticlePubMedGoogle Scholar
- Hazkani-Covo E, Covo S: Numt-mediated double-strand break repair mitigates deletions during primate genome evolution. PLoS Genet. 2008, 4: e1000237-10.1371/journal.pgen.1000237.PubMed CentralView ArticlePubMedGoogle Scholar
- Ricchetti M, Tekaiam F, Dujon B: Continued colonization of the human genome by mitochondrial DNA. PLoS Biol. 2004, 2: E273-10.1371/journal.pbio.0020273.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuan JD, Shi JX, Meng GX, An LG, et al: Nuclear pseu-dogenes of mitochondrial DNA as a variable part of the human genome. Cell Res. 1999, 9: 281-290. 10.1038/sj.cr.7290027.View ArticlePubMedGoogle Scholar
- Turner C, Killoran C, Thomas NS, Rosenberg M, et al: Human genetic disease caused by de novo mitochondrial-nuclear DNA transfer. Hum Genet. 2003, 112: 303-309.PubMedGoogle Scholar
- Goldin E, Stahl S, Cooney AM, Kaneski CR, et al: Transfer of a mitochondrial DNA fragment to MCOLN1 causes an inherited case of mucolipidosis IV. Hum Mutat. 2004, 24: 460-465. 10.1002/humu.20094.View ArticlePubMedGoogle Scholar
- Chen JM, Chuzhanova N, Stenson PD, Férec C, et al: Meta-analysis of gross insertions causing human genetic disease: novel mutational mechanisms and the role of replication slippage. Hum Mutat. 2005, 25: 207-221. 10.1002/humu.20133.View ArticlePubMedGoogle Scholar
- Borensztajn K, Chafa O, Alhenc-Gelas M, Salha S, et al: Characterization of two novel splice site mutations in human factor VII gene causing severe plasma factor VII deficiency and bleeding diathesis. Br J Haematol. 2002, 117: 168-171. 10.1046/j.1365-2141.2002.03397.x.View ArticlePubMedGoogle Scholar
- Giampieri C, Centurelli M, Olivieri F, et al: A novel mitochondrial DNA-like sequence insertion polymorphism in intron I of the FOXO1A gene. Gene. 2004, 327: 215-219. 10.1016/j.gene.2003.11.003.View ArticlePubMedGoogle Scholar